Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Google Halts UK YouTube TV Measurement Service After Legal Action 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
NEW YORK, May 17, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:
- UBS Global Healthcare Conference on May 23, 2017 at 2:30 p.m. Eastern Time
- Jefferies Healthcare Conference on June 8, 2017 at 2:00 p.m. Eastern Time
- Goldman Sachs 38th Annual Healthcare Conference on June 13, 2017 at 11:20 a.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
